Hepatology

Experts in hepatology discuss disease progression of PBC and the long-term complications patients may experience.

David Victor III, MD, comments on the risk factors for PBC and the importance of educating the patient about the disease.

The point prevalence per 100,000 people at the conclusion of the study was 71.8 for autoimmune hepatitis, 38.5 for primary biliary cholangitis, and 11.0 for primary sclerosing cholangitis.

For individuals with hepatitis C virus infections, 52.5% of deaths were deemed attributable to the infection.

The approval makes odevixibat the second IBAT inhibitor approved for the rare genetic disease, with capability to benefit both liver damage and itch symptoms.

Patients with autoimmune hepatitis who were positive for antimitochondrial antibodies and evidence of non-specific bile duct injury had a higher risk of progressing to cirrhosis.

Edward Mena, MD, reviews the classification and diagnosis of PBC considering the change from the term “cirrhosis” to “cholangitis.”

Sonal Kumar, MD, MPH, provides an overview of primary biliary cholangitis (PBC) and its recent increase in prevalence, as well as common signs and symptoms.

A cascade-of-care analysis of the country's largest tribally-operated health system showed clear gaps in progressing patients with HCV from diagnosis to completed treatment.

The IBAT inhibitor will receive an FDA decision by next week. Ovchinsky reviews its supporting data for benefitting patient pruritus, sleep, and liver bile acid levels.

An emerging drug class is proving viable for burdensome symptoms, as well as liver failure, in pediatric patients with the rare inherited disease.

There was an association between NAFLD in the South-Asian population and diabetes mellitus, hypertension, dyslipidemia, general obesity, central obesity and metabolic syndrome.

The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.

In a recent interview, Kris Kowdley, MD, discusses current data surrounding use of GLP-1 receptor agonists in NAFLD and NASH as well as the prospective role of combination agents.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

The genetic rare disease is characterized by a greater risk of premature mortality and worsened quality of life. Emerging IBAT inhibitors are helping address both issues.

The 2030 goal for global elimination of HCV looks out of reach so as key patient population including those who inject drugs are out of clinician's reach, one expert explains.

Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.

The investigators also found impaired biosynthesis of short-chain fatty acids in the coprofiltrate after analyzing the intestinal microbiome of patients with NAFLD who had SARS-CoV-2, manifested by an increase in the median acetic and propionic acids, as well as a decrease in the median butyric acid.

Counties with high liver transplantation registration rates and high liver-related mortality rates had comparable data on social vulnerability index, while travel distance was relatively shorter.

All countries in Africa now provide a three-dose infant hepatitis B vaccination beginning at age 6-8 weeks.

There is some concern that the prevalence of diseases like NASH and NAFLD may increase in the coming years.